Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Status
Claims 1-21 are currently pending in this application.
Election/Restrictions
Election was made with traverse of Group I, claims 1-4, and without traverse the species of SEQ ID NO: 12, position 587, polypeptide and retinal cell disease in the reply filed on April 24, 2026. Claims 5-10 and 14-21 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected groups of inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 04/24/26. Claims 1-4 and 11-13 were considered on the merits, and all arguments were fully considered.
Status of Rejections
The previous claim rejections under 35 USC §§ 112(a), 112(b), 102, and 103 in view of the claim amendments, except as maintained below.
Claim Interpretation
In claim 2, the term “VP1 encoded amino acid sequence of the parental AAV2/AAV9 capsid protein” is interpreted as referring to a VP1 protein encoded by a gene (Cap) or ORF (Cap ORF), whether naturally occurring or synthetic (see instant [0131]-[0132], [0140], [0147]).
In claim 3, the further point mutation “708I” is interpreted as requiring the specific amino acid substitution V708I (wherein V is a valine residue and I is an isoleucine residue) positionally based on SEQ ID NO: 1 numbering. See instant [0203], FIG. 2; [0023]-[0024].
Claim Rejections - 35 USC § 112(a), Written Description (modified)
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1, 3, and 11-13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement for failing to particularly point out and distinctly claim the subject matter. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
The claimed invention as a whole is not adequately described if the claims require essential or critical elements that are not adequately described in the specification and that is not conventional in the art as of applicant’s effective filing date. Possession may be shown by actual reduction to practice, clear depiction of the invention in a detailed drawing, or by describing the invention with sufficient relevant identifying characteristics such that a person skilled in the art would recognize that the inventor had possession of the claimed invention. Pfaff v. Wells Electronics, Inc., 48 USPQ2d 1641,1646 (1998).
In making a determination of whether the application complies with the written description requirement under 35 U.S.C. 112(a) or 35 U.S.C. 112, first paragraph, it is necessary to understand what Applicant is claiming and what Applicant has possession of. The invention of claim 1 or 11 is respectively an AAV capsid protein variant comprising an insert of instant SEQ ID NO: 12 or any polynucleotide encoding the aforementioned.
Insert Position
Claim 1 is broad in that said insert polypeptide may be at any position in any AAV capsid protein so long as the insert is SEQ ID NO: 12 or 18. The preamble of “adeno-associated virus (AAV) capsid protein” implies the limitation that the protein must somehow function as an AAV capsid protein (e.g., as its parental AAV capsid protein) despite variations therefrom. However it must be emphasized that the scope of claims 1, 3, and 11-13 encompasses insertions with no limitation in position. Thus, claim 1 is broad in that said insert polypeptide (SEQ ID NO: 12 or 18) may be at any position in any AAV capsid protein so long as the modified AAV capsid protein possesses at least one known AAV capsid protein functionality. This genus of variants encompasses more than 2,900 protein species just based on the two parental AAV capsid proteins consisting of SEQ ID NO: 1 or 37, not to mention VP1, VP2 and VP3 proteins of other AAV serotypes or based on synthetic AAV capsid proteins known in the prior art.
In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described.
The instant application provides clear examples of species of such claimed proteins related to a parental VP1 protein modified to have an insertion between position 588 (VP1 AAV2) and verified to retain a partial (e.g., minimal) AAV capsid protein activity of a known AAV capsid protein (e.g., a VP1 capsid protein function) (Table 1, Example 2; SEQ ID NO: 4, 9 and 23). Further, the instant specification describes prophetic embodiments comprising differing insert positions.
The prior art teaches that insertions of small peptides (6-10 amino acids) into AAV2 capsid proteins at various positions (e.g., at position 10, 24, 39, 76, 84, 150, 178, 203, 328, 454, 522, 526, 547, 553, 562, 638, 664, or 682) and some can destroy protein function, damage virion production, and/or produce defective virions (Wu et al., J Virol 74: 8635-47 (2000) at Table 2; Fig. 1, 3). For example, certain insertions resulted in “noninfectious” virions having an infectivity 5-logs lower compared to wild-type due to being unable to make capsids or failing to make stable capsids (class 4b) or being defective in a host cell binding, internalization, and/or uncoating step(s) (class 4a or 4d) (Wu at Table 2; Fig. 3). In another example, while some prior art teaches AAV2 capsid proteins permits some insertions at position 587, other prior art shows unpredictability at this same 587 position with insertions (e.g., NLS) causing a six-fold reduction in capsid assembly, ten-fold drop in packaging efficiency, loss of host cell binding, and drastic reductions in infectivity (Douar et al. Virology 309: 203-9 (2003); at Abstract; Table 1; Fig. 2-3C; pg. 206, left col., last para., to right col., 2nd para.).
Thus in view of the art, it is unpredictable for a functional AAV capsid protein (VP1, VP2, or VP3 capsid protein) to tolerate insertions at any position and it was not predictable a priori which positions will or will not tolerate a given peptide sequence as an insert at a given position without empirical testing. As the prior art does not teach any predictable pattern for permissive insertion sites, these aspects must be described to a reasonable extent so that one of the ordinary skills in the art would recognize that Applicant was in possession of these insertion sites at the effective filing date of the claimed invention. Furthermore, as the prior art teaches away specifically from specific positions (e.g., in the core β-sheet or basic regions or specifically in a PLA2, BR3, or BR4 domain, or at position 39, 150, 454, and/or 587), more convincing evidence is required to sufficiently describe to one of skill in the art that Applicant was in possession of unlimited insertion sites and especially certain specific insertion sites in view of the prior art evidence.
Thus, the genus of position-unlimited insertions is not sufficiently described by a representative number of species. As taught by the art, AAV capsid protein function is too unpredictable in general and, specifically, for various specific insertional positions demonstrated to dramatically perturb AAV2 VP2 protein function. Therefore in the instant case, empirical evidence is needed to show possession for any insertion position as the skilled artisan cannot envision the full scope of claim 1 predictably providing at least one minimum AAV capsid protein functionality. Instead, direct detailed description was provided only for the AAV capsid protein variants consisting essentially of SEQ ID NOs: 4, 9, and 23 by showing retention of AAV capsid protein functionality after insertion. Thusly, predictable description was provided only for the AAV capsid protein variants predictable from such SEQ ID NOs: 4, 9, and 23 species, such as the full genus of claim 2 or 4.
Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed” (pg 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed” (pg 1116). As discussed above, the skilled artisan cannot envision the structure(s) of the insertions regarding position and a parental AAV capsid protein (e.g., AAV2 VP1 such as instant SEQ ID NO:1) allowing for preservation of at least partial AAV capsid protein function based on the information provided in the instant application. Adequate written description requires more than a mere statement that it is part of the invention and reference to potential and generic ways of modifying any AAV capsid protein via insertion at virtually any location. Therefore, the claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventors, at the time the application was filed, had possession of the full scope of the invention as claimed.
Response to arguments
Applicant’s arguments in the response of 8/31/26 regarding the 112(a) rejections (pg. 7) were only found partially persuasive. No argument was made regarding the vast positional variations and sequence diversity as encompassed by most of the instant claims.
Claim Rejections - 35 USC § 112(b) (new)
The following is a quotation of 35 U.S.C. 112(b):
(B) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 2 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
Claim 2 recites “the parental AAV2 capsid protein” and “the parental AAV9 capsid protein,” each of which lacks sufficient antecedent basis in both claims 1 and 2.
Allowable Subject Matter
Claim 4 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ERIC J ROGERS whose telephone number is (571)272-8338. The examiner can normally be reached Monday - Friday 9:00-6:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached on (571) 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ERIC J ROGERS/
Examiner, Art Unit 1638
/JAMES D SCHULTZ/Supervisory Patent Examiner, Art Unit 1631